Clozapine has been the most effective antipsychotic in schizophrenia for almost 40 years, yet it is still routinely held back until patients have failed multiple alternatives over many years — a “third-line, after years of failure” default that a 2026 Current Opinion review by Davani et al. argues is no longer supported by the evidence.1 …
Adding music to ketamine psychotherapy failed to provide extra antidepressant benefit over matched non-music support in a 2026 randomized clinical trial (RCT; a study that assigns participants to groups by chance), even though the full 6-infusion ketamine-psychotherapy course was followed by large depression-score reductions. Research Highlights Music added no confirmed MADRS benefit: in the MUSIK …
A 2026 systematic review and meta-analysis of randomized trials found no broad superiority for phase-based complex PTSD care across most outcomes. Affect dysregulation was the clearest exception, improving more when treatment was phase-based, multi-phase, and exposure-containing. Research Highlights Most therapy formats helped: across waitlist and treatment-as-usual comparisons, psychological interventions reduced PTSD symptoms (k = 9; …
Popular coverage of chronotype neuroimaging usually claims that late chronotypes (evening types, often called “night owls”) show smaller cortical regions and faster brain aging than early chronotypes (morning types). A 2026 multimodal structural MRI analysis from Beheshti and Elkana ran the comparison in 136 healthy young adults using strict whole-brain correction, and the group differences …
A 2025 preregistered meta-analysis found that temporary social media abstinence did not significantly improve positive affect, negative affect, or life satisfaction across 10 adult experiments involving 4,674 participants.1 The result does not prove that every break is useless, but it challenges the generic “digital detox” claim that simply logging off reliably improves mood. Research Highlights …
Psychiatric brain biomarkers have produced a large research literature but little routine clinical use. A 2026 evidence map found 441 primary studies and 27 systematic reviews of neuroimaging or neurophysiologic biomarkers for mental-health disorders, yet the field still looks too small, cross-sectional, and depression-heavy for ordinary diagnostic or treatment decisions.1 Research Highlights Large map, weak …
GLP-1 drugs are usually described as appetite drugs, but a 2026 Nature mouse study mapped a more specific reward circuit: small-molecule GLP-1 receptor agonists suppressed palatable-food intake through Glp1r-expressing central-amygdala neurons that reduced dopamine release in the nucleus accumbens during high-fat-food retrieval.1 That mechanism makes binge-eating and substance-use hypotheses more plausible without turning an animal …